#35 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians should be aware that cannabis pet products are entering the legal market with pharmaceutical-grade testing standards, which means patients may increasingly ask about cannabinoid use for their pets’ pain, anxiety, or other conditions. Understanding the evidence base and regulatory status of these products will help clinicians provide informed guidance on safety, efficacy, and drug interactions, particularly since pets may have different cannabinoid metabolism than humans. As the pet cannabis market expands with legal products, clinicians should stay current on emerging research about endocannabinoid system function in animals to counsel patients appropriately about risks and benefits.
Proof has launched a cannabis-derived pet product in California that undergoes pharmaceutical-grade testing and quality assurance, recognizing that companion animals possess endocannabinoid systems similar to humans. The product represents a regulated alternative to unvetted pet cannabis formulations currently available in the market, addressing concerns about product safety, potency accuracy, and contaminant exposure in animals. As more pet owners explore cannabis for conditions such as pain, anxiety, and seizures in dogs and cats, the availability of standardized, tested products may reduce risks associated with inconsistent dosing or contaminated preparations. Clinicians should be aware that pet owners may inquire about cannabis use in their animals or present with pets showing adverse effects from unregulated products, making knowledge of available regulated options relevant to veterinary and even primary care discussions about household exposures. The practical takeaway is that clinicians should ask pet-owning patients about cannabis product use in their animals and recommend regulated, tested formulations over unvetted alternatives when patients express interest in this therapeutic approach.
“The endocannabinoid system in animals functions similarly to humans, which means we should approach cannabis products for pets with the same clinical rigor we apply to human medicine, including third-party testing and dose standardization, rather than treating them as an unregulated supplement category.”
💊 While the emerging market for cannabis products in pets reflects genuine scientific interest in the endocannabinoid system shared across mammalian species, veterinarians should approach these products with appropriate caution given the limited rigorous clinical evidence in animal populations. Current pet cannabis products lack the robust safety and efficacy data standard for veterinary pharmaceuticals, and state-level regulation of cannabis products—even those marketed as “100% legal”—does not guarantee the same quality oversight or clinical validation that pharmaceutical-grade medications receive. Confounding factors such as placebo effects in owner-perceived outcomes, variable cannabinoid concentrations across products, and the potential for drug interactions with conventional medications remain inadequately characterized in veterinary medicine. When clients inquire about cannabis-based treatments for their pets’ pain, anxiety, or other conditions, clinicians should acknowledge the biological plausibility of endocannabinoid system involvement while honestly discussing the evidence gap, documenting
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: